ExaWizards and ExaMD Present Findings from a Wearable Device Study on Breast Cancer Patients—A Joint Research Project with Kansai Medical University, Daiichi Sankyo, and Others—at the American Society of Clinical Oncology “ASCO 2026” ‐Aiming to develop new digital AI healthcare services based on the analysis results‐

ExaWizards Inc. (Minato-ku, Tokyo; Representative Director, President & CEO : Makoto Haruta; hereinafter “ExaWizards”) and its group company ExaMD Inc. (Minato-ku, Tokyo; Representative Director, Koji Hazama; hereafter, “ExaMD”), which develops and provides AI services in the health and medical fields, are pleased to announce that the findings of “TRACK-BC” (hereinafter “this Study”)—a wearable-data utilization study targeting early-stage breast cancer patients conducted by Kansai Medical University Hospital (hereinafter “Kansai Medical University”), Daiichi Sankyo Company, Limited (hereinafter “Daiichi Sankyo”), and others, in whose analysis the companies participated together with TechDoctor Inc. (hereinafter “TechDoctor”)—were presented at the 2026 ASCO Annual Meeting, hosted by the American Society of Clinical Oncology, one of the world’s largest oncology-related academic societies.

☑Purpose and Social Significance of this Study
Preoperative chemotherapy for early-stage breast cancer is generally administered on an outpatient basis, and understanding patients’ conditions during their daily lives has become an important challenge. Breast cancer also has a high incidence rate in the working-age population (mainly those in their 40s and 50s), posing a significant challenge to women’s continued employment and reintegration into society.

The goal of this Study is to collect daily data (physical activity, sleep, and heart rate) from wearable devices (Google Fitbit, etc.), along with patients’ subjective physical condition data recorded via smartphone (electronic Patient-Reported Outcomes; hereinafter “ePRO”) to evaluate changes in physical activity levels associated with chemotherapy and their relationship with changes in a patient’s physical and mental conditions. Objectively clarifying trends in this collected data will make it easier for working women undergoing treatment to establish support systems while planning their work schedules and life events. This observational study to comprehensively capture data under daily-life conditions is attracting considerable attention for its future utilization in medical care and research.

☑Overview of the Conference Presentation
・Conference Name: 2026 ASCO Annual Meeting (American Society of Clinical Oncology)
・Study Title: “A Prospective Observational Study Evaluating Physical Activity Levels Using Wearable Devices in Early-Stage Breast Cancer Patients Initiating Neoadjuvant Chemotherapy (TRACK-BC)”
・Principal Investigator: Dr. Yuichiro Kikawa, Clinical Professor, Department of Breast Surgery, Kansai Medical University General Medical Center (Affiliated with Kansai Medical University Hospital at the start of the study)
・Presenter: Dr. Nobuhiro Shibata, Lecturer, Department of Clinical Oncology, Kansai Medical University Hospital

For this Study, ExaWizards and ExaMD developed the ePRO/Electronic Data Capture (hereinafter “EDC”) system to allow patients to easily enter and manage their daily physical condition for data analysis work and to support research.

☑Initiatives with Daiichi Sankyo
ExaWizards and ExaMD have continued joint initiatives with Daiichi Sankyo to solve social issues in the medical and healthcare fields. This presentation represents the advancement of the breast cancer observational study steadily pursued by both companies alongside the joint research group, led by Kansai Medical University.

*Previous initiatives between ExaWizards and Daiichi Sankyo related to this research (announced in 2023): https://exawizards.com/en/archives/27694/

☑Future Outlook
Detailed analysis results from this Study will be reported in future academic presentations and journals. The findings from this Study will allow ExaWizards and ExaMD to develop and deploy future digital AI healthcare services as they work toward a society where patients can continue their treatment while living their daily lives.